KR101170654B1 - 효모에서의 ｈｐｖ 58 ｌ1의 최적화된 발현 - Google Patents

효모에서의 ｈｐｖ 58 ｌ1의 최적화된 발현 Download PDF

Info

Publication number
KR101170654B1
KR101170654B1 KR1020067009199A KR20067009199A KR101170654B1 KR 101170654 B1 KR101170654 B1 KR 101170654B1 KR 1020067009199 A KR1020067009199 A KR 1020067009199A KR 20067009199 A KR20067009199 A KR 20067009199A KR 101170654 B1 KR101170654 B1 KR 101170654B1
Authority
KR
South Korea
Prior art keywords
hpv58
yeast
protein
delete delete
codon
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
KR1020067009199A
Other languages
English (en)
Korean (ko)
Other versions
KR20060122852A (ko
Inventor
재닌 티 브라이언
미셸 케이 브라운로우
로렌 디 슐츠
진-민 왕
카트린 유 얀센
Original Assignee
머크 샤프 앤드 돔 코포레이션
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 머크 샤프 앤드 돔 코포레이션 filed Critical 머크 샤프 앤드 돔 코포레이션
Publication of KR20060122852A publication Critical patent/KR20060122852A/ko
Application granted granted Critical
Publication of KR101170654B1 publication Critical patent/KR101170654B1/ko
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/01—DNA viruses
    • C07K14/025—Papovaviridae, e.g. papillomavirus, polyomavirus, SV40, BK virus, JC virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
    • C12N15/81—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20023—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/22—Vectors comprising a coding region that has been codon optimised for expression in a respective host

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Communicable Diseases (AREA)
  • Plant Pathology (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
KR1020067009199A 2003-11-12 2004-11-10 효모에서의 ｈｐｖ 58 ｌ1의 최적화된 발현 Expired - Lifetime KR101170654B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US51921103P 2003-11-12 2003-11-12
US60/519,211 2003-11-12
PCT/US2004/037372 WO2005047315A2 (en) 2003-11-12 2004-11-10 Optimized expression of hpv 58 l1 in yeast

Publications (2)

Publication Number Publication Date
KR20060122852A KR20060122852A (ko) 2006-11-30
KR101170654B1 true KR101170654B1 (ko) 2012-08-03

Family

ID=34590374

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020067009199A Expired - Lifetime KR101170654B1 (ko) 2003-11-12 2004-11-10 효모에서의 ｈｐｖ 58 ｌ1의 최적화된 발현

Country Status (32)

Country Link
US (2) US7498036B2 (enExample)
EP (1) EP1687329B8 (enExample)
JP (2) JP4912885B2 (enExample)
KR (1) KR101170654B1 (enExample)
CN (1) CN1942583B (enExample)
AR (1) AR046835A1 (enExample)
AT (1) ATE452977T1 (enExample)
AU (1) AU2004290032B2 (enExample)
BE (1) BE2015C070I2 (enExample)
BR (1) BRPI0416393B1 (enExample)
CA (1) CA2543928C (enExample)
CY (2) CY1113875T1 (enExample)
DE (1) DE602004024821D1 (enExample)
DK (1) DK1687329T3 (enExample)
ES (1) ES2340287T3 (enExample)
FR (1) FR15C0081I2 (enExample)
HU (1) HUS1500064I1 (enExample)
IL (1) IL175353A (enExample)
IS (1) IS2741B (enExample)
LT (1) LTC1687329I2 (enExample)
LU (1) LU92901I2 (enExample)
MY (1) MY139500A (enExample)
NL (1) NL300775I2 (enExample)
NO (3) NO340633B1 (enExample)
NZ (1) NZ546697A (enExample)
PL (1) PL1687329T3 (enExample)
PT (1) PT1687329E (enExample)
RU (1) RU2370538C2 (enExample)
SI (1) SI1687329T1 (enExample)
TW (1) TWI332988B (enExample)
WO (1) WO2005047315A2 (enExample)
ZA (1) ZA200603106B (enExample)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7858098B2 (en) * 2002-12-20 2010-12-28 Glaxosmithkline Biologicals, S.A. Vaccine
US8206950B2 (en) 2003-06-09 2012-06-26 Animal Technology Institute Taiwan Fusion antigen used as vaccine and method of making them
ES2343255T3 (es) 2004-03-24 2010-07-27 MERCK SHARP & DOHME CORP. Expresion optimizada del vph 52 l1 en levadura.
US20070243587A1 (en) * 2006-04-14 2007-10-18 Healthbanks Biotech Co., Ltd. Using a reverse genetic engineering platform to produce protein vaccines and protein vaccine of avian influenza virus
CN101148661B (zh) * 2006-09-18 2013-01-02 中国医学科学院基础医学研究所 人乳头瘤病毒16型外壳蛋白病毒样颗粒及其制备方法和用途
WO2008112125A1 (en) * 2007-03-09 2008-09-18 Merck & Co., Inc. Papillomavirus vaccine compositions
EP2154147B1 (en) 2007-04-29 2015-10-07 Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. A truncated l1 protein of human papillomavirus 16
DK2147926T3 (en) 2007-04-29 2016-11-28 Beijing Wantai Biological Pharmacy Entpr Co Ltd Truncated human papillomavirus type 18 L1 protein
WO2008145021A1 (fr) * 2007-05-29 2008-12-04 Xiamen University Protéine l1 tronquée du papillomavirus humain de type 6
CN101113417B (zh) * 2007-06-22 2011-04-27 山东大学 Hpv基因酵母体外翻译系统的建立
CN101200696B (zh) * 2007-11-14 2011-07-20 山东大学 人乳头瘤病毒的酵母增殖模型及建立方法与应用
MY182347A (en) * 2007-11-23 2021-01-20 Shanghai Zerun Biotechnology Co Ltd Genes encoding major capsid protein l1 of human papilloma virus and use of the same
KR20090073987A (ko) * 2007-12-31 2009-07-03 정운원 인간유두종바이러스 유전자형 검사를 위한 프라이머, 프로브 및 이를 포함하는 ｄｎａ칩, 이의 검사 방법 및 검사 키트
JP5726727B2 (ja) * 2008-05-26 2015-06-03 カディラ・ヘルスケア・リミテッド 麻疹−ヒトパピローマ混合ワクチン
US9335868B2 (en) * 2008-07-31 2016-05-10 Apple Inc. Capacitive sensor behind black mask
EP2576840B1 (en) 2010-05-25 2018-10-17 QIAGEN Gaithersburg, Inc. Fast results hybrid capture assay and associated strategically-truncated probes
CN101857870B (zh) * 2010-06-12 2012-09-05 上海泽润生物科技有限公司 Hpv58 l1基因及载体、菌株和表达方法
EP2594579B1 (en) * 2010-07-16 2015-04-15 Xiamen University Truncated human papillomavirus type 58 l1 protein
CN102154325B (zh) * 2011-01-01 2013-08-21 上海生物制品研究所有限责任公司 针对人乳头瘤状病毒的疫苗及其制法和用途
EP2722389B1 (en) * 2011-06-15 2018-03-07 Hong Jin Kim Method for enhancing the production yield of human papillomavirus l1 protein
CN108624614A (zh) * 2012-03-28 2018-10-09 北京安百胜生物科技有限公司 用汉逊酵母表达系统产生hpv11 l1蛋白的方法
CA2875945A1 (en) 2012-06-07 2013-12-12 The Children's Hospital Of Philadelphia Controlled gene expression methods
CN103992395B (zh) * 2013-02-18 2018-07-27 北京康乐卫士生物技术股份有限公司 重组hpv-58型l1的vlp疫苗及其制备方法
CN104120088B (zh) * 2013-04-26 2019-09-24 北京安百胜生物科技有限公司 用汉逊酵母表达系统产生hpv58 l1蛋白的方法
CN104164374B (zh) * 2013-05-17 2019-10-22 北京安百胜生物科技有限公司 用汉逊酵母表达系统产生hpv31 l1蛋白的方法
CN104164373B (zh) * 2013-05-17 2019-04-02 北京安百胜生物科技有限公司 用汉逊酵母表达系统产生hpv68l1蛋白的方法
EP3057612B1 (en) 2013-10-16 2020-05-06 Merck Sharp & Dohme Corp. Method of obtaining thermostable dried vaccine formulations
EA201790365A1 (ru) * 2014-09-11 2017-07-31 Кадила Хелзкэр Лимитед Антигены вируса папилломы человека с хорошими иммунологическими свойствами и содержащая их вакцина
CN117187263A (zh) * 2015-03-30 2023-12-08 上海泽润生物科技有限公司 重组人乳头瘤病毒33亚型蛋白表达
CN104878022A (zh) * 2015-04-27 2015-09-02 段青姣 编码hpv58l1、hpv52l1蛋白的核苷酸序列及其应用
WO2017092710A1 (zh) * 2015-12-04 2017-06-08 厦门大学 一种人乳头瘤病毒58型l1蛋白的突变体
US11638754B2 (en) 2020-02-14 2023-05-02 Merck Sharp & Dohme Llc HPV vaccine
CN113073105B (zh) * 2021-03-23 2023-06-13 重庆博唯佰泰生物制药有限公司 一种表达hpv 56l1的多核苷酸序列及其表达载体、宿主细胞和应用
CN113549634B (zh) * 2021-06-07 2023-03-31 郑州大学 编码可溶性hpv58 l1蛋白的基因及其重组质粒的构建与应用
US20230048144A1 (en) 2021-08-06 2023-02-16 Merck Sharp & Dohme Llc Hpv vaccine
MX2024002144A (es) 2021-08-19 2024-04-23 Merck Sharp & Dohme Llc Nueva nanoparticula lipidica termostable y metodos de uso de la misma.
TW202513091A (zh) 2023-06-09 2025-04-01 美商默沙東有限責任公司 用於人類乳突病毒疫苗之奈米乳液佐劑組合物
CN117054647A (zh) * 2023-07-17 2023-11-14 广东省一鼎生物技术有限公司 一种检测HPV IgG抗体试剂盒及其制备方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5821087A (en) 1995-03-30 1998-10-13 Merck & Co., Inc. Production of recombinant human papillomavirus type II protein utilizing papillomavirus 6/11 hybrid DNA
IL117591A0 (en) 1995-03-30 1996-07-23 Merck & Co Inc Synthetic DNA encoding human papillomavirus type 11 L1 protein
JP2001512308A (ja) 1997-02-07 2001-08-21 メルク エンド カンパニー インコーポレーテッド 合成ｈｉｖ ｇａｇ遺伝子
EP1002091B1 (en) 1997-07-09 2012-02-29 Coridon Pty Limited Nucleic acid sequence and method for selectively expressing a protein in a target cell or tissue
PL347472A1 (en) * 1998-08-14 2002-04-08 Merck & Co Inc Process for purifying human papillomavirus virus-like particles
ATE344052T1 (de) 1998-08-14 2006-11-15 Merck & Co Inc Protein-verabreichungssystem, das dem menschlichen papillomavirus ähnliche partikel benützt.
SE514982C2 (sv) * 1999-09-30 2001-05-28 Active Biotech Ab Bärare innehållande ett huvudkapsidprotein L1 från humant papillomavirus samt dess användning
WO2001014416A2 (en) 1999-08-25 2001-03-01 Merck & Co., Inc. Synthetic papillomavirus genes optimized for expression in human cells
US6436402B1 (en) 1999-10-15 2002-08-20 Merck & Co., Inc. Process for making human papillomavirus virus-like particles with improved properties
US7026443B1 (en) * 1999-12-10 2006-04-11 Epimmune Inc. Inducing cellular immune responses to human Papillomavirus using peptide and nucleic acid compositions
PT1301614E (pt) 2000-07-21 2007-02-28 Group Limited Glaxo Sequências de codão optimizado do vírus do papiloma
WO2003068163A2 (en) * 2002-02-14 2003-08-21 Novavax, Inc. Optimization of gene sequences of chimeric virus-like particles for expression in insect cells
CA2519112C (en) 2003-03-24 2012-09-11 Merck & Co., Inc. Optimized expression of hpv 31 l1 in yeast
MY140664A (en) * 2003-09-29 2010-01-15 Merck Sharp & Dohme Optimized expression of hpv 45 l1 in yeast

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
Journal of Virology, 1999, Vol. 73, No. 6, pp.4972-4982
NCBI, GenBank accession number: NC_001443.1 (2000.04.03.)*
Vaccine, 2001, Vol.20, No. 5-6, pp.862-868
Vaccine, 2003, Vol. 21, pp. 1539-1547*

Also Published As

Publication number Publication date
NL300775I1 (enExample) 2015-12-29
LU92901I2 (fr) 2016-03-08
AU2004290032A1 (en) 2005-05-26
HUS1500064I1 (hu) 2016-02-29
NZ546697A (en) 2009-05-31
JP2012095652A (ja) 2012-05-24
US20100272749A1 (en) 2010-10-28
EP1687329B1 (en) 2009-12-23
ZA200603106B (en) 2007-09-26
IS8425A (is) 2006-04-21
IL175353A (en) 2010-11-30
FR15C0081I2 (fr) 2016-11-25
DK1687329T3 (da) 2010-04-12
RU2370538C2 (ru) 2009-10-20
BE2015C070I2 (enExample) 2023-12-18
EP1687329B8 (en) 2010-03-17
US7976848B2 (en) 2011-07-12
DE602004024821D1 (de) 2010-02-04
WO2005047315A2 (en) 2005-05-26
WO2005047315A3 (en) 2006-09-28
CN1942583A (zh) 2007-04-04
BRPI0416393B1 (pt) 2021-06-29
CY2015051I1 (el) 2016-06-22
IS2741B (is) 2011-06-15
NO2017058I1 (no) 2017-11-10
MY139500A (en) 2009-10-30
SI1687329T1 (sl) 2010-03-31
NO340633B1 (no) 2017-05-15
BRPI0416393A (pt) 2007-04-03
KR20060122852A (ko) 2006-11-30
PL1687329T3 (pl) 2010-06-30
NL300775I2 (enExample) 2015-12-29
CA2543928C (en) 2011-04-05
US20070036824A1 (en) 2007-02-15
JP4912885B2 (ja) 2012-04-11
IL175353A0 (en) 2006-09-05
CY1113875T1 (el) 2016-06-22
CY2015051I2 (el) 2016-06-22
RU2006120402A (ru) 2007-12-27
JP5616879B2 (ja) 2014-10-29
AR046835A1 (es) 2005-12-28
LTC1687329I2 (lt) 2017-05-10
CN1942583B (zh) 2010-10-27
PT1687329E (pt) 2010-02-26
NO2022052I1 (no) 2022-11-30
US7498036B2 (en) 2009-03-03
ES2340287T3 (es) 2010-06-01
JP2008500019A (ja) 2008-01-10
FR15C0081I1 (fr) 2016-08-01
AU2004290032B2 (en) 2009-02-05
TW200519203A (en) 2005-06-16
NO20062674L (no) 2006-06-09
EP1687329A2 (en) 2006-08-09
CA2543928A1 (en) 2005-05-26
ATE452977T1 (de) 2010-01-15
TWI332988B (en) 2010-11-11

Similar Documents

Publication Publication Date Title
KR101170654B1 (ko) 효모에서의 ｈｐｖ 58 ｌ1의 최적화된 발현
KR101165278B1 (ko) 효모에서의 ｈｐｖ 45 ｌ1의 최적화된 발현
US7744892B2 (en) Optimized expression of HPV 52 L1 in yeast
MXPA06005306A (en) Optimized expression of hpv 58 l1 in yeast

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20060511

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20091102

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20110503

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20120430

N231 Notification of change of applicant
PN2301 Change of applicant

Patent event date: 20120711

Comment text: Notification of Change of Applicant

Patent event code: PN23011R01D

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20120727

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20120730

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
PR1001 Payment of annual fee

Payment date: 20150630

Start annual number: 4

End annual number: 4

A101 Application to extend term of patent right by permit
PA0101 Application to register extension of term of patent right by permit, etc.

Patent event date: 20160425

Patent event code: PA01011R01D

Comment text: Application to Register Extension of Term of Patent Right by Permit, etc.

FPAY Annual fee payment

Payment date: 20160629

Year of fee payment: 5

PR1001 Payment of annual fee

Payment date: 20160629

Start annual number: 5

End annual number: 5

FPAY Annual fee payment

Payment date: 20170629

Year of fee payment: 6

PR1001 Payment of annual fee

Payment date: 20170629

Start annual number: 6

End annual number: 6

FPAY Annual fee payment

Payment date: 20180628

Year of fee payment: 7

PR1001 Payment of annual fee

Payment date: 20180628

Start annual number: 7

End annual number: 7

FPAY Annual fee payment

Payment date: 20190624

Year of fee payment: 8

PR1001 Payment of annual fee

Payment date: 20190624

Start annual number: 8

End annual number: 8

PR1001 Payment of annual fee

Payment date: 20200624

Start annual number: 9

End annual number: 9

PR1001 Payment of annual fee

Payment date: 20230626

Start annual number: 12

End annual number: 12

PR1001 Payment of annual fee

Payment date: 20240624

Start annual number: 13

End annual number: 13